Draft:Jeff Galvin (entrepreneur)
| Submission declined on 26 March 2024 by CNMall41 (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: This was obviously written by someone with a close connection to the subject. There is a lot of work needed to cut down the promotional tone. First, please read WP:COI and WP:PAID and make the appropriate disclosures if applicable. CNMall41 (talk) 06:25, 26 March 2024 (UTC)
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by CNMall41 (talk | contribs) 2 months ago. (Update)
Finished drafting? or |
Jeff Galvin | |
|---|---|
 Jeff Galvin in 2023 | |
| Born | June 13, 1958 |
| Education | Bachelor of Arts in Economics from Harvard University in 1981. |
| Occupation(s) | Entrepreneur and CEO in Biotechnology |
| Organization(s) | Montgomery County Public Schools, Cancer Support Community, Maryland Tech Council, INFORM Rare Disease Conference |
| Known for | Biotechnology Entrepreneurship |
| Spouse | Qi Tang (Wife) |
| Parent | Aaron Galvin (Father) |
| Honours | See Recognition section |
| Website | https://www.linkedin.com/in/jeff-galvin/ |
Jeffery A. Galvin (born June 13, 1958) is an American entrepreneur, investor, and business owner. Galvin is best known for his entrepreneurship in the biotechnology space, including the founding of gene therapy companies American Gene Technologies® (AGT) and Addimmune[1][2].
After graduating from Harvard in 1981, Galvin begun his career in Silicon Valley, where he worked in executives positions and founded a variety of start-ups, many of which were sold to public companies[3]. He then retired in 2002 to become an angel investor in real estate and high-tech, until he met with Roscoe Brady, a NIH researcher, in 2006[4]. Brady introduced Galvin to viral vectors and their potential in gene therapy, inspiring Galvin to enter the biotechnology industry[4]. Galvin then founded American Gene Technologies in 2007 to pursue the use of gene therapy as a potential cure a variety of diseases.[citation needed] He is the CEO of Maryland-based biotech company American Gene Technologies (AGT), and is expected to be named CEO of Addimmune, a newly formed HIV research company, following its public listing early in 2024.
Early Life[edit]
According to an interview with LI Intake, he taught a weekend class at MIT on basic computer programming to high school and college students at the age of 14 after being informed that they currently did not have any weekend classes on computers[5]. Galvin then eventually went to Harvard where we was a head teaching fellow for some of the largest classes and graduated with a degree in economics in 1981[5].
Early Business Career in Silicon Valley[edit]
Upon graduation from Harvard University, Galvin began working at Hewlett-Packard's CSY Division as a software engineer.[6]. Dissatisfied with the repetitive nature of the job, Galvin moved on to Apple where he became an international product marketing manager, a job which he was more naturally suited for[7]
Following his successful career at Apple, Galvin spent the next 4 years in sales and marketing between Blyth Software and Claris Software, but when he found himself craving a a technical challenge, Galvin pivoted back into engineering and software development[7]. 5 years at Argus software, 2 years at Command Audio Corporation, and a year at Allin Consulting centered Galvin in his area of expertise, as an entrepreneur and a VP/director of technical projects like software development and engineering[8]. Many of Galvin's startups were bought by public companies, such as Argus software, a medical technology company, which was acquired by Varian Medical Systems in 2002[8]. Galvin retired from high tech and start-ups in 2002 to Hawaii, where he became an angel investor in high tech and real estate[9].
Entry into Biotechnology[edit]
Galvin's introduction to the biotechnology industry came in 2006, when he met with NIH researcher Roscoe Brady. Brady introduced Galvin to the technology of viral vectors, which are a technology that take advantage of virus' ability to insert their genetic code into cells in order to deliver genetic information to human cells for disease treatment purposes[4]. This meeting inspired Galvin to come out of retirement and enter the field of biotechnology, specifically gene and cell therapy, starting with the founding of American Gene Technologies (AGT) in Rockville, Maryland in 2007[10]. Galvin founded AGT with the goal of utilizing the power of gene therapy in order to relieve people from serious diseases, such as HIV, Cancer, Phenylketonuria (PKU), etc[11].
Since its founding in 2007, AGT, with Galvin as CEO, has introduced programs for finding cures for HIV, liver cancer, pancreatic cancer, PKU, and more, all using the lentiviral vector technology created by AGT[11]. The HIV cure program entered the phase one of clinical trials in 2020 with its AGT103-T drug and successfully completed this phase in late 2022, publishing the data in the science journal Frontiers[12]. The success with this trial led Galvin to launch a new spinoff company named Addimmune in 2023 that focuses solely on the potential HIV cure, while AGT focuses on gene therapy for other monogenetic diseases and cancer[13][14].
Recognitions[edit]
- Life Sciences Voice Top Industry Leaders Award (2023)[15]
- NABOE World Changing Business Award (2023)[16]
- Montgomery County Business Hall of Fame Honoree (2022)[17]
- Moxie Award for Healthcare & Biotech (2021)[18]
- Maryland Tech Council CEO of the Year Nominee (2021)[19]
- Northern Virginia Chamber of Commerce Mid-Atlantic Innovator of the Year & People's Choice Winner (2021)[20]
- BioBuzz Breakthrough Company of the Year (2020)[21]
See also[edit]
- ^ "Jeffrey A. Galvin | Cancer Support Community". www.cancersupportcommunity.org. Retrieved 2023-07-25.
- ^ "Jeff Galvin, CEO and Founder". Addimmune. Retrieved 2023-07-25.
- ^ "CEO and Founder Jeffrey A. Galvin". American Gene Technologies. Retrieved 2023-07-25.
- ^ a b c "American Gene Technologies | Maryland Business Success Story". business.maryland.gov. Retrieved 2023-07-25.
- ^ a b "Jeff Galvin - LI Intake Interview.docx". Google Docs. Retrieved 2023-07-27.
- ^ "This biotech's 'Microsoft' approach could change how we see gene therapy". PharmaVoice. Retrieved 2023-07-26.
- ^ a b Goldstein, David (2020-08-17). "Rockville cell and gene company may have found treatment for HIV". MoCo360. Retrieved 2023-07-26.
- ^ a b Philippidis, Alex (2023-07-07). "AGT Spins Out Addimmune, Focusing on Functional HIV Cure". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-07-26.
- ^ https://shadygrove.umd.edu/sites/default/files/MCBHOF%20Event%20Program%202022%20single%20pages%20w%20no%20crop.pdf
- ^ Eckert, Andy (2020-08-04). "5 Questions with Jeff Galvin, CEO and Founder of American Gene Technologies™". BioBuzz. Retrieved 2023-07-25.
- ^ a b "Development Portfolio and Patents at AGT". American Gene Technologies. Retrieved 2023-07-25.
- ^ Muvarak, Nidal; Li, Haishan; Lahusen, Tyler; Galvin, Jeffrey A.; Kumar, Princy N.; Pauza, C. David; Bordon, José (2022). "Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial". Frontiers in Medicine. 9. doi:10.3389/fmed.2022.1044713. ISSN 2296-858X. PMC 9701732. PMID 36452901.
- ^ "American Gene Technologies® Launches New Spinoff Company "Addimmune™" to Focus Exclusively on Development of HIV Cure". PRWeb. Retrieved 2023-07-25.
- ^ "Rockville's American Gene Technologies launches spinout Addimmune". www.bizjournals.com. Retrieved 2023-07-25.
- ^ "Jeff Galvin Wins Life Sciences Voice 2023 Top Industry Leaders Award". American Gene Technologies. Retrieved 2023-07-25.
- ^ "American Gene Technologies Twitter". Twitter. Retrieved 2023-07-26.
- ^ "Honorees | Montgomery County Business Hall of Fame". Retrieved 2023-07-25.
- ^ "Moxie Award 2021 Winners". Moxie Award. Retrieved 2023-07-25.
- ^ "Maryland Tech Council Announces 2021 Industry Awards Celebration Finalists". Maryland Tech Council. 2021-03-22. Retrieved 2023-07-26.
- ^ "Mid-Atlantic Innovation Awards Names HumanTouch, 2021 People's Choice Winner | Optimer". www.humantouchllc.com. Retrieved 2023-07-25.
- ^ Frew, Chris (2020-12-15). "Meet Your 2020 BioBuzz Award Winners". BioBuzz. Retrieved 2023-07-25.